Published in Expert Opin Ther Targets on October 01, 2006
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol (2009) 3.61
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist (2007) 3.42
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst (2009) 2.16
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol (2010) 1.67
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res (2006) 1.58
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer (2006) 1.50
Alternate endpoints for screening phase II studies. Clin Cancer Res (2009) 1.47
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol (2009) 1.40
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol (2011) 1.29
Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol (2006) 1.29
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials. J Clin Oncol (2010) 1.23
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res (2013) 1.22
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
A review of erlotinib and its clinical use. Expert Opin Pharmacother (2006) 1.18
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer (2013) 1.16
Neuroendocrine tumors of the gastrointestinal tract: a decade of experience at the Princess Margaret Hospital. Am J Clin Oncol (2008) 1.11
Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol (2010) 1.05
Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res (2012) 1.02
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol (2002) 1.01
Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol (2005) 1.01
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs (2013) 0.99
A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol (2010) 0.97
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. Oncologist (2014) 0.96
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol (2005) 0.95
Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.93
A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer (2005) 0.93
A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol (2005) 0.92
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs (2010) 0.92
Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol (2004) 0.91
Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer. J Clin Oncol (2008) 0.91
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs (2003) 0.89
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs (2010) 0.89
Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol (2007) 0.89
Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors. Acta Oncol (2009) 0.87
A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat (2007) 0.87
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? J Clin Oncol (2007) 0.86
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest New Drugs (2006) 0.85
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs (2013) 0.84
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer. Invest New Drugs (2011) 0.84
A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer. Oncologist (2008) 0.83
Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial. Support Care Cancer (2002) 0.83
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer. Cancer Chemother Pharmacol (2010) 0.83
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs (2009) 0.82
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol (2005) 0.82
Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days. Invest New Drugs (2004) 0.82
Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.80
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res (2006) 0.80
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol (2012) 0.80
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. J Thorac Oncol (2009) 0.80
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs (2011) 0.77
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer (2013) 0.76
Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia. J Clin Oncol (2008) 0.76
Depression and use of health care services in patients with advanced cancer. Can Fam Physician (2013) 0.75
Surgical oncology: Is PBD suitable for resectable pancreatic cancer? Nat Rev Clin Oncol (2010) 0.75
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol (2005) 0.75
Targeting metastatic prostate cancer: the search for innovative systemic therapies. Oncology (Williston Park) (2006) 0.75
Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum. Acta Oncol (2004) 0.75
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer (2013) 0.75
Eyelid metastasis from mediastinal teratoma with malignant transformation. Acta Oncol (2007) 0.75